Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
OBJECTIVE
To determine the relationship between the antibiotic susceptibility of Pseudomonas aeruginosa isolated from the sputum of patients with cystic fibrosis (CF) and the patient's response to parenteral antibiotic administration, we performed a retrospective analysis using data from patients in the placebo arm of a phase 3 trial of tobramycin solution for inhalation. All patients were chronically infected with P aeruginosa. Seventy-seven of the 262 patients receiving placebo experienced a pulmonary exacerbation during the trial for which they received therapy with IV tobramycin and ceftazidime. The susceptibility of the P aeruginosa isolates to ceftazidime and tobramycin was determined at trial enrollment by broth microdilution.


METHODS
The clinical response to combination antibiotic therapy was assessed by analyzing differences in spirometry before and after antibiotic administration. The FEV(1) percent predicted at the first visit after the conclusion of antibiotic administration was compared to the FEV(1) percent predicted prior to antibiotic therapy. The results were analyzed both descriptively and by regression analyses.


RESULTS
The conditions of 54 patients improved, and those of 9 patients worsened, and in 14 patients there was no change in FEV(1) with antibiotic administration. No correlation was observed between the susceptibility of P aeruginosa to tobramycin or ceftazidime and clinical response. Only the three following variables were observed to significantly correlate with FEV(1) after antibiotic treatment on regression analysis: FEV(1) prior to treatment (p < 0.0001); number of days elapsed between the previous FEV(1) measurement and the initiation of IV antibiotic therapy (p < 0.002); and the number of days elapsed between the determination of the minimum inhibitory concentration and the initiation of IV therapy (p < 0.03). No significant trends were observed between the antibiotic susceptibility of P aeruginosa isolates and treatment outcomes.


CONCLUSIONS
While lack of statistical significance for a trend between bacterial susceptibilities and the response to parenteral antibiotic administration does not mean that no such trend exists, the precision of the confidence intervals allows us to conclude that even if isolate antibiotic susceptibilities affect outcome, the impact would be small and not clinically relevant.
Smith
Arnold L
AL
Seattle Biomedical Research Institute, WA 98109, USA. arnold.smith@sbri.org
Fiel
Stanley B
SB
Mayer-Hamblett
Nicole
N
Ramsey
Bonnie
B
Burns
Jane L
JL
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology; D002442:Ceftazidime / Q000008:administration & dosage / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000382:microbiology* / Q000503:physiopathology; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D007275:Injections, Intravenous; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013183:Sputum / Q000382:microbiology*; D014031:Tobramycin / Q000008:administration & dosage / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002442:Ceftazidime; D014031:Tobramycin